Senescent cells promote cancer through SASP-driven secretion of growth factors, proteases, and inflammatory mediators that stimulate adjacent pre-cancerous cells. Fisetin's senolytic activity reduces this tumor-promoting environment while also directly inhibiting cancer cell proliferation through PI3K/AKT/mTOR pathway inhibition.

Can fisetin be used alongside cancer treatment?

Preliminary data suggests fisetin may sensitize some cancer cells to chemotherapy, but this requires medical supervision. Inform your oncologist of any supplements during cancer treatment.

Does removing senescent cells increase cancer risk?

This concern has been raised theoretically. However, animal studies consistently show that senolytic treatment reduces — not increases — tumor incidence and growth. Oncogene-induced senescence (OIS) arrests pre-cancerous cells, but age-associated senescence is distinct and generally tumor-promoting via SASP.